Cover Image

Does Rivaroxaban Better than Vitamin K Antagonists in Atrial Fibrillation Patients Undergoing PCI?

<p>ACS: Acute Coronary Syndrome; AF: Atrial Fibrillation; DAPT: Dual Antiplatelet Therapy; INR: InternationalNormalized Ratio; MI: Myocardial Infarction; PCI: Percutaneous Coronary Intervention; PIONEER AF-PCI: Open-Label, Randomized, Controlled, Multicenterstudy Exploring two Treatment Strate...

Full description

Saved in:

Bibliographic Details
Main Authors:	Maamar Kara (Author), Omar Aitmokhtar (Author), Adel Azaza (Author), Saber Seddiki (Author), Faiza Harbi (Author), Arezki Sik (Author), Kheireddine Merad (Author), Salim Benkhedda (Author)
Format:	Book
Published:	Archives of Hematology Case Reports and Reviews - Peertechz Publications, 2016-12-30.
Subjects:	Editorial
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Rivaroxaban in atrial fibrillation cardioversion: an update
by: Lavalle C, et al.
Published: (2019)

The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin
by: I. Yu. Koroleva, et al.
Published: (2016)

RIVAROXABAN IN THE PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION
by: M. Yu. Gilyarov
Published: (2015)

RIVAROXABAN IN THE PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION
by: M. Yu. Gilyarov
Published: (2015)

Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation
by: Turpie AGG
Published: (2014)

Atrial fibrillation in elderly patients. Features of using rivaroxaban
by: A. D. Erlikh
Published: (2020)

ATRIAL FIBRILLATION COMBINED WITH DIABETES MELLITUS. POSSIBILITIES OF USING RIVAROXABAN
by: Alexey D. Ehrlich
Published: (2018)

Pharmacogenetics and pharmacokinetics of rivaroxaban in patients with atrial fibrillation and chronic kidney disease
by: N. A. Shatalova, et al.
Published: (2023)

The Role of Rivaroxaban in a Comprehensive Protection Strategy for Patients with Atrial Fibrillation
by: I. A. Zolotovskaya, et al.
Published: (2021)

Rivaroxaban Precision Dosing Strategy for Real‐World Atrial Fibrillation Patients
by: Robyn Konicki, et al.
Published: (2020)

Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban
by: Francisco Marin, et al.
Published: (2023)

Interaction of rivaroxaban with amiodarone, verapamil and diltiazem in patients with atrial fibrillation: terra incognita
by: S. N. Bel'diev
Published: (2016)

Effect of Rivaroxaban in Stroke Prevention in Patient with Atrial Fibrillation due to Valvular Heart Disease
by: Waqar shamim, et al.
Published: (2022)

Time Trends in Patient Characteristics of New Rivaroxaban Users with Atrial Fibrillation in Germany and the Netherlands
by: Annemarie Voss, et al.
Published: (2023)

Comparative Bleeding Risk of Brand Vs Generic Rivaroxaban in Elderly Inpatients with Atrial Fibrillation
by: Chen G, et al.
Published: (2024)

Twice-daily rivaroxaban after percutaneous left atrial appendage closure for atrial fibrillation
by: Yang-Qi Pan, et al.
Published: (2024)

CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: S. V. Nedogoda, et al.
Published: (2017)

Co-Administration of Amiodarone Increases Bleeding by Affecting Rivaroxaban Pharmacokinetics in Patients with Atrial Fibrillation
by: Huamin Ding, et al.
Published: (2024)

Cost‐effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China
by: Hongtao Wei, et al.
Published: (2021)

Comparison of the Effectiveness of Rivaroxaban Versus Vitamin K Antagonist in Patients with Lower Limbs Deep Vein Thrombosis
by: Safi Ullah, et al.
Published: (2024)

Influence of ABCB1 Gene Polymorphism on Rivaroxaban Blood Concentration and Hemorrhagic Events in Patients With Atrial Fibrillation
by: Yan Wang, et al.
Published: (2021)

Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US
by: Miller JD, et al.
Published: (2016)

Application of rivaroxaban in clinical practice: results of a prospective observational study XANTUS in patients with atrial fibrillation
by: S. G. Kanorskii
Published: (2016)

THE SPECIFICS OF PRESCRIBING TRIPLE ANTITROMBOTIC THERAPY WITH RIVAROXABAN IN PATIENTS WITH ATRIAL FIBRILLATION AFTER CORONARY ARTERY STENTING
by: N. A. Novikova, et al.
Published: (2017)

An Integrated Approach to the Management of a Multimorbid Patient with Atrial Fibrillation from the Standpoint of Modern Guidelines: Rivaroxaban is in Focus
by: V. N. Larina, et al.
Published: (2021)

Possibilities of Using Rivaroxaban in Elderly Patients with Atrial Fibrillation: Data from Randomized Studies and Real Clinical Practice
by: N. M. Vorobyeva, et al.
Published: (2018)

Population Pharmacokinetics and Dose Optimization Based on Renal Function of Rivaroxaban in Thai Patients with Non-Valvular Atrial Fibrillation
by: Noppaket Singkham, et al.
Published: (2022)

ASPECTS OF MULTICOMPONENT THERAPY AND PERIOPERATIVE TACTICS IN A PATIENT WITH ATRIAL FIBRILLATION RECEIVING RIVAROXABAN THERAPY. CLINICAL OBSERVATION
by: O. A. Zemlyanskaya, et al.
Published: (2019)

THE USE OF MINERALOCORTICOID RECEPTOR ANTAGONISTS IN THE PRE VENTION OF ATRIAL FIBRILLATION
by: N. T. Vatutin, et al.
Published: (2019)

Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK
by: Kevin Bowrin, et al.
Published: (2020)

Clinical profile and management of rivaroxaban in patients with atrial fibrillation in routine practice in Spain: data from six nationwide studies
by: Manuel Anguita, et al.
Published: (2019)

Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study
by: Maxim Grymonprez, et al.
Published: (2023)

Evaluation of Remote Pharmacist-Led Outpatient Service for Geriatric Patients on Rivaroxaban for Nonvalvular Atrial Fibrillation During the COVID-19 Pandemic
by: Xiaoye Li, et al.
Published: (2020)

Clinical Efficacy and Safety Comparison of Rivaroxaban and Dabigatran for Nonvalvular Atrial Fibrillation Patients Undergoing Percutaneous Left Atrial Appendage Closure Operation
by: Xiaoye Li, et al.
Published: (2021)

Benefits and Harms of Low-Dose Rivaroxaban in Asian Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis of Real-World Studies
by: Jun Qian, et al.
Published: (2021)

EFFICACY AND SAFETY OF DIRECT ORAL ANTICOAGULANTS IN THE PREVENTION OF STROKE IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION IN EVERYDAY CLINICAL PRACTICE: FACTS ABOUT RIVAROXABAN
by: I. S. Yavelov
Published: (2016)

Cost effectiveness of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients in Saudi Arabia: A Single-Center retrospective cohort study
by: Yazed AlRuthia, et al.
Published: (2023)

New data of the real clinical practice confirms low incidence of major bleeding when using rivaroxaban in patients with non-valvular atrial fibrillation
by: article Editorial
Published: (2015)

New data of the real clinical practice confirms low incidence of major bleeding when using rivaroxaban in patients with non-valvular atrial fibrillation
by: article Editorial
Published: (2015)

New data of the real clinical practice confirms low incidence of major bleeding when using rivaroxaban in patients with non-valvular atrial fibrillation
by: article Editorial
Published: (2015)